Literature DB >> 19645482

Discovery of a highly potent, selective, and bioavailable soluble epoxide hydrolase inhibitor with excellent ex vivo target engagement.

Hong C Shen1, Fa-Xiang Ding, Siyi Wang, Qiaolin Deng, Xiaoping Zhang, Yuli Chen, Gaochao Zhou, Suoyu Xu, Hsuan-Shen Chen, Xinchun Tong, Vincent Tong, Kaushik Mitra, Sanjeev Kumar, Christine Tsai, Andra S Stevenson, Lee-Yuh Pai, Magdalena Alonso-Galicia, Xiaoli Chen, Stephen M Soisson, Sophie Roy, Bei Zhang, James R Tata, Joel P Berger, Steven L Colletti.   

Abstract

4-Substituted piperidine-derived trisubstituted ureas are reported as highly potent and selective inhibitors for sEH. The SAR outlines approaches to improve activity against sEH and reduce ion channel and CYP liability. With minimal off-target activity and a good PK profile, the benchmark 2d exhibited remarkable in vitro and ex vivo target engagement. The eutomer entA-2d also elicited vasodilation effect in rat mesenteric artery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19645482     DOI: 10.1021/jm900725r

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  17 in total

Review 1.  Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications.

Authors:  Hong C Shen; Bruce D Hammock
Journal:  J Med Chem       Date:  2012-01-17       Impact factor: 7.446

Review 2.  Targeting epoxides for organ damage in hypertension.

Authors:  John D Imig
Journal:  J Cardiovasc Pharmacol       Date:  2010-10       Impact factor: 3.105

3.  Design, synthesis and evaluation of non-urea inhibitors of soluble epoxide hydrolase.

Authors:  Stevan Pecic; Shi-Xian Deng; Christophe Morisseau; Bruce D Hammock; Donald W Landry
Journal:  Bioorg Med Chem Lett       Date:  2011-10-28       Impact factor: 2.823

4.  Incorporation of piperazino functionality into 1,3-disubstituted urea as the tertiary pharmacophore affording potent inhibitors of soluble epoxide hydrolase with improved pharmacokinetic properties.

Authors:  Shao-Xu Huang; Hui-Yuan Li; Jun-Yan Liu; Christophe Morisseau; Bruce D Hammock; Ya-Qiu Long
Journal:  J Med Chem       Date:  2010-11-11       Impact factor: 7.446

5.  Computer-Aided Fragment Growing Strategies to Design Dual Inhibitors of Soluble Epoxide Hydrolase and LTA4 Hydrolase.

Authors:  Lena Hefke; Kerstin Hiesinger; W Felix Zhu; Jan S Kramer; Ewgenij Proschak
Journal:  ACS Med Chem Lett       Date:  2020-04-08       Impact factor: 4.345

6.  Antiproliferative 4-(1,2,4-oxadiazol-5-yl)piperidine-1-carboxamides, a new tubulin inhibitor chemotype.

Authors:  Mikhail Krasavin; Andrey V Sosnov; Ruben Karapetian; Igor Konstantinov; Olga Soldatkina; Elena Godovykh; Fedor Zubkov; Ruoli Bai; Ernest Hamel; Andrei A Gakh
Journal:  Bioorg Med Chem Lett       Date:  2014-08-08       Impact factor: 2.823

7.  Pharmacokinetic screening of soluble epoxide hydrolase inhibitors in dogs.

Authors:  Hsing-Ju Tsai; Sung Hee Hwang; Christophe Morisseau; Jun Yang; Paul D Jones; Takeo Kasagami; In-Hae Kim; Bruce D Hammock
Journal:  Eur J Pharm Sci       Date:  2010-03-30       Impact factor: 4.384

Review 8.  Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health.

Authors:  Christophe Morisseau; Bruce D Hammock
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012-09-27       Impact factor: 13.820

9.  1-Aryl-3-(1-acylpiperidin-4-yl)urea inhibitors of human and murine soluble epoxide hydrolase: structure-activity relationships, pharmacokinetics, and reduction of inflammatory pain.

Authors:  Tristan E Rose; Christophe Morisseau; Jun-Yan Liu; Bora Inceoglu; Paul D Jones; James R Sanborn; Bruce D Hammock
Journal:  J Med Chem       Date:  2010-10-14       Impact factor: 7.446

Review 10.  Epoxides and soluble epoxide hydrolase in cardiovascular physiology.

Authors:  John D Imig
Journal:  Physiol Rev       Date:  2012-01       Impact factor: 37.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.